Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs
High-dose statin treatment has been recommended as a primary strategy for aggressive reduction of LDL cholesterol levels and protection against coronary artery disease. The effectiveness of high-dose statins may be limited by their potential for myotoxic side effects. There is currently little known...
Saved in:
Published in | Toxicology and applied pharmacology Vol. 223; no. 1; pp. 39 - 45 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
San Diego, CA
Elsevier Inc
15.08.2007
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | High-dose statin treatment has been recommended as a primary strategy for aggressive reduction of LDL cholesterol levels and protection against coronary artery disease. The effectiveness of high-dose statins may be limited by their potential for myotoxic side effects. There is currently little known about the molecular mechanisms of statin-induced myotoxicity. Previously we showed that T-91485, an active metabolite of the squalene synthase inhibitor lapaquistat acetate (lapaquistat: a previous name is TAK-475), attenuated statin-induced cytotoxicity in human skeletal muscle cells [Nishimoto, T., Tozawa, R., Amano, Y., Wada, T., Imura, Y., Sugiyama, Y., 2003a. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A. Biochem. Pharmacol. 66, 2133–2139]. In the current study, we investigated the effects of lapaquistat administration on statin-induced myotoxicity
in vivo. Guinea pigs were treated with either high-dose cerivastatin (1 mg/kg) or cerivastatin together with lapaquistat (30 mg/kg) for 14 days. Treatment with cerivastatin alone decreased plasma cholesterol levels by 45% and increased creatine kinase (CK) levels by more than 10-fold (a marker of myotoxicity). The plasma CK levels positively correlated with the severity of skeletal muscle lesions as assessed by histopathology. Co-administration of lapaquistat almost completely prevented the cerivastatin-induced myotoxicity. Administration of mevalonolactone (100 mg/kg b.i.d.) prevented the cerivastatin-induced myotoxicity, confirming that this effect is directly related to HMG-CoA reductase inhibition. These results strongly suggest that cerivastatin-induced myotoxicity is due to depletion of mevalonate derived isoprenoids. In addition, squalene synthase inhibition could potentially be used clinically to prevent statin-induced myopathy. |
---|---|
AbstractList | High-dose statin treatment has been recommended as a primary strategy for aggressive reduction of LDL cholesterol levels and protection against coronary artery disease. The effectiveness of high-dose statins may be limited by their potential for myotoxic side effects. There is currently little known about the molecular mechanisms of statin-induced myotoxicity. Previously we showed that T-91485, an active metabolite of the squalene synthase inhibitor lapaquistat acetate (lapaquistat: a previous name is TAK-475), attenuated statin-induced cytotoxicity in human skeletal muscle cells [Nishimoto, T., Tozawa, R., Amano, Y., Wada, T., Imura, Y., Sugiyama, Y., 2003a. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A. Biochem. Pharmacol. 66, 2133–2139]. In the current study, we investigated the effects of lapaquistat administration on statin-induced myotoxicity
in vivo. Guinea pigs were treated with either high-dose cerivastatin (1 mg/kg) or cerivastatin together with lapaquistat (30 mg/kg) for 14 days. Treatment with cerivastatin alone decreased plasma cholesterol levels by 45% and increased creatine kinase (CK) levels by more than 10-fold (a marker of myotoxicity). The plasma CK levels positively correlated with the severity of skeletal muscle lesions as assessed by histopathology. Co-administration of lapaquistat almost completely prevented the cerivastatin-induced myotoxicity. Administration of mevalonolactone (100 mg/kg b.i.d.) prevented the cerivastatin-induced myotoxicity, confirming that this effect is directly related to HMG-CoA reductase inhibition. These results strongly suggest that cerivastatin-induced myotoxicity is due to depletion of mevalonate derived isoprenoids. In addition, squalene synthase inhibition could potentially be used clinically to prevent statin-induced myopathy. High-dose statin treatment has been recommended as a primary strategy for aggressive reduction of LDL cholesterol levels and protection against coronary artery disease. The effectiveness of high-dose statins may be limited by their potential for myotoxic side effects. There is currently little known about the molecular mechanisms of statin-induced myotoxicity. Previously we showed that T-91485, an active metabolite of the squalene synthase inhibitor lapaquistat acetate (lapaquistat: a previous name is TAK-475), attenuated statin-induced cytotoxicity in human skeletal muscle cells [Nishimoto, T., Tozawa, R., Amano, Y., Wada, T., Imura, Y., Sugiyama, Y., 2003a. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A. Biochem. Pharmacol. 66, 2133-2139]. In the current study, we investigated the effects of lapaquistat administration on statin-induced myotoxicity in vivo. Guinea pigs were treated with either high-dose cerivastatin (1 mg/kg) or cerivastatin together with lapaquistat (30 mg/kg) for 14 days. Treatment with cerivastatin alone decreased plasma cholesterol levels by 45% and increased creatine kinase (CK) levels by more than 10-fold (a marker of myotoxicity). The plasma CK levels positively correlated with the severity of skeletal muscle lesions as assessed by histopathology. Co-administration of lapaquistat almost completely prevented the cerivastatin-induced myotoxicity. Administration of mevalonolactone (100 mg/kg b.i.d.) prevented the cerivastatin-induced myotoxicity, confirming that this effect is directly related to HMG-CoA reductase inhibition. These results strongly suggest that cerivastatin-induced myotoxicity is due to depletion of mevalonate derived isoprenoids. In addition, squalene synthase inhibition could potentially be used clinically to prevent statin-induced myopathy. |
Author | Ishikawa, Eiichiro Nagai, Hirofumi Anayama, Hisashi Tozawa, Ryuichi Hirakata, Masao Hamajyo, Hitomi Nishimoto, Tomoyuki |
Author_xml | – sequence: 1 givenname: Tomoyuki surname: Nishimoto fullname: Nishimoto, Tomoyuki organization: Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan – sequence: 2 givenname: Eiichiro surname: Ishikawa fullname: Ishikawa, Eiichiro organization: Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan – sequence: 3 givenname: Hisashi surname: Anayama fullname: Anayama, Hisashi organization: Development Research Center, Takeda Pharmaceutical Company Limited, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan – sequence: 4 givenname: Hitomi surname: Hamajyo fullname: Hamajyo, Hitomi organization: Development Research Center, Takeda Pharmaceutical Company Limited, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan – sequence: 5 givenname: Hirofumi surname: Nagai fullname: Nagai, Hirofumi organization: Development Research Center, Takeda Pharmaceutical Company Limited, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan – sequence: 6 givenname: Masao surname: Hirakata fullname: Hirakata, Masao organization: Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan – sequence: 7 givenname: Ryuichi surname: Tozawa fullname: Tozawa, Ryuichi email: Ryuichi_Tozawa@takeda.co.jp organization: Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19018760$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17599378$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/21077778$$D View this record in Osti.gov |
BookMark | eNp9kU9r3DAQxUVJaTZpv0APRVBaWojdkSWvLOglhP6jgfaQQm9ClsdZLV7Ja8mhe-tHr8wu5NbTCM3vDfPmXZAzHzwS8pJByYCtP2zLZMxYVgCyhLoEqJ-QFQO1LoBzfkZWAIIVAM3vc3IR4xYAlBDsGTlnslaKy2ZF_v6cQkKb3ANS7Pv8ijT01NC4n82AHmk8-LQxEanzG9e6FKYrOpjR7GcXk0nUWMwF6bu76--FkPX7Kxo8XVrOF853s8WO7g4hhT_OunTIc-j97DwaOrr7-Jw87c0Q8cWpXpJfnz_d3Xwtbn98-XZzfVtYIXgqGlEDVqLtRMtNb1uDvKm6WiFgzSpWd9jwXkrZQubaPv_JVqqWCyYU9Kbhl-T1cW6IyemYN0G7scH7bFlXDLJWLtTbIzVOYT9jTHrnosVhMB7DHDVTkqtasAxWR9BOIcYJez1Obmemg2agl3T0Vi_p6CUdDbXO6WTRq9P0ud1h9yg5xZGBNyfARGuGfjLeuvjIKWCNXEPmPh45zBd7cDgthtDnS7tp8dMF9789_gGJWK_G |
CODEN | TXAPA9 |
CitedBy_id | crossref_primary_10_1038_bjp_2008_143 crossref_primary_10_1097_CRD_0b013e3181885905 crossref_primary_10_1517_14728214_13_2_309 crossref_primary_10_3389_fchem_2014_00050 crossref_primary_10_1161_CIRCULATIONAHA_111_028571 crossref_primary_10_2165_00129784_200808040_00003 crossref_primary_10_3390_cancers12061410 crossref_primary_10_1111_nure_12011 crossref_primary_10_1002_jhet_1514 crossref_primary_10_1586_erc_12_112 crossref_primary_10_1111_jam_13053 crossref_primary_10_1097_MOL_0b013e3282f169c6 crossref_primary_10_1155_2018_1854972 crossref_primary_10_1007_s11883_009_0011_0 crossref_primary_10_1194_jlr_M016089 crossref_primary_10_1097_BOR_0b013e328317a234 crossref_primary_10_1124_jpet_116_239574 crossref_primary_10_1016_j_bmc_2015_09_034 crossref_primary_10_1016_j_bmc_2007_10_001 crossref_primary_10_1007_s40279_014_0224_4 crossref_primary_10_1016_j_pharmthera_2010_02_006 crossref_primary_10_1007_s11886_008_0080_7 crossref_primary_10_1016_j_bbrc_2024_150046 crossref_primary_10_1016_j_tox_2015_01_005 crossref_primary_10_3390_cells9112352 crossref_primary_10_15252_emmm_201404000 crossref_primary_10_1016_j_bmc_2023_117378 |
Cites_doi | 10.1016/S0753-3322(01)00150-0 10.1016/j.bcp.2003.08.011 10.2165/00003495-200060050-00011 10.1016/S0002-9149(03)00779-3 10.1016/S0140-6736(02)09327-3 10.1006/taap.1997.8174 10.1006/abio.1997.2309 10.1111/j.1527-3466.2004.tb00131.x 10.1001/jama.257.16.2176 10.1006/taap.1997.8131 10.1016/S0002-9149(99)00120-4 10.1093/jn/131.1.10 10.1001/archinte.141.9.1128 10.1185/03007990152005351 10.1038/sj.bjp.0705332 10.1067/mcp.2002.128469 10.1002/mus.20291 10.1001/jama.279.20.1615 10.1056/NEJMoa040583 10.1056/NEJM199610033351401 10.1016/S0014-2999(03)01549-8 10.1016/j.taap.2004.04.010 10.1001/jama.291.9.1071 10.1016/S0022-2275(20)37182-0 |
ContentType | Journal Article |
Copyright | 2007 Elsevier Inc. 2007 INIST-CNRS |
Copyright_xml | – notice: 2007 Elsevier Inc. – notice: 2007 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U7 C1K OTOTI |
DOI | 10.1016/j.taap.2007.05.005 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Toxicology Abstracts Environmental Sciences and Pollution Management OSTI.GOV |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | Toxicology Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1096-0333 |
EndPage | 45 |
ExternalDocumentID | 21077778 10_1016_j_taap_2007_05_005 17599378 19018760 S0041008X0700227X |
Genre | Journal Article |
GroupedDBID | --- --K --M .55 .GJ .HR .~1 0R~ 123 1B1 1RT 1~. 1~5 29Q 3O- 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKC AAIKJ AAKOC AALRI AAMNW AAOAW AAQFI AAQXK AATCM AAXUO ABEFU ABFNM ABFRF ABFYP ABJNI ABLST ABMAC ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AFFNX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHEUO AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AKIFW ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLECG BLXMC C45 CAG COF CS3 DM4 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KCYFY KOM LG5 M33 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SPT SSJ SSP SSZ T5K TEORI TWZ UHS WH7 WUQ X7M XJT XPP Y6R YCJ ZGI ZKB ZMT ZU3 ZXP ~G- ~KM 08R AAPBV AAUGY ABPIF ABPTK IQODW AAXKI AKRWK CGR CUY CVF ECM EIF NPM AAYXX AFJKZ CITATION 7U7 C1K AALMO ABQIS EFJIC OTOTI |
ID | FETCH-LOGICAL-c443t-8450e24bd4b3afcbae382d59e0e51215de83f777b050ebf5127b79b341490fa83 |
IEDL.DBID | AIKHN |
ISSN | 0041-008X |
IngestDate | Thu May 18 22:22:41 EDT 2023 Fri Aug 16 07:19:32 EDT 2024 Thu Sep 26 19:22:03 EDT 2024 Sat Sep 28 07:42:40 EDT 2024 Sun Oct 22 16:06:01 EDT 2023 Fri Feb 23 02:28:19 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Squalene synthase inhibitor Statin Guinea pigs Lapaquistat acetate Myotoxicity TAK-475 Enzyme Toxicity Transferases Rodentia Statin derivative Acetate Farnesyl-diphosphate farnesyltransferase Prevention Vertebrata Mammalia Guinea pig Lapaquistat Animal Antilipemic agent |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c443t-8450e24bd4b3afcbae382d59e0e51215de83f777b050ebf5127b79b341490fa83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17599378 |
PQID | 19739541 |
PQPubID | 23462 |
PageCount | 7 |
ParticipantIDs | osti_scitechconnect_21077778 proquest_miscellaneous_19739541 crossref_primary_10_1016_j_taap_2007_05_005 pubmed_primary_17599378 pascalfrancis_primary_19018760 elsevier_sciencedirect_doi_10_1016_j_taap_2007_05_005 |
PublicationCentury | 2000 |
PublicationDate | 2007-08-15 |
PublicationDateYYYYMMDD | 2007-08-15 |
PublicationDate_xml | – month: 08 year: 2007 text: 2007-08-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | San Diego, CA |
PublicationPlace_xml | – name: San Diego, CA – name: United States |
PublicationTitle | Toxicology and applied pharmacology |
PublicationTitleAlternate | Toxicol Appl Pharmacol |
PublicationYear | 2007 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Sacks, Pfeffer, Moye, Rouleau, Rutherford, Cole, Brown, Warnica, Arnold, Wun, Davis, Braunwald (bib24) 1996; 335 Amano, Nishimoto, Tozawa, Ishikawa, Imura, Sugiyama (bib1) 2003; 466 Plosker, Dunn, Figgitt (bib23) 2000; 60 Stein, Isaacsohn, Stoltz, Mazzu, Liu, Lane, Heller (bib26) 1999; 83 Baker (bib4) 2005; 31 Gordon, Kannel, Castelli, Dawber (bib12) 1981; 141 Nishimoto, Tozawa, Amano, Wada, Imura, Sugiyama (bib18) 2003; 66 Bliznakov (bib5) 2002; 56 Perez, Kupfer, Chen, Law (bib21) 2006; 114 (bib25) 1994; 344 Brewer (bib6) 2003; 92 Flint, Masters, Gregg, Durham (bib11) 1997; 145 Backman, Kyrklund, Neuvonen, Neuvonen (bib3) 2002; 72 Illingworth, Crouse, Hunninghake, Davidson, Escobar, Stalenhoef, Paragh, Ma, Liu, Melino, O'Grady, Mercuri, Mitchel (bib15) 2001; 17 Johnson, Zhang, Bleicher, Dysart, Loughlin, Schaefer, Umbenhauer (bib16) 2004; 200 Matzno, Yamauchi, Gohda, Ishida, Katsuura, Hanasaki, Tokunaga, Itoh, Nakamura (bib17) 1997; 38 Cannon, Braunwald, McCabe, Rader, Rouleau, Belder, Joyal, Hill, Pfeffer, Skene (bib7) 2004; 350 Flint, Masters, Gregg, Durham (bib10) 1997; 145 Nishimoto, Amano, Tozawa, Ishikawa, Imura, Yukimasa, Sugiyama (bib19) 2003; 13 Piper, Price, Chen (bib22) 2006; 114 Anderson, Castelli, Levy (bib2) 1987; 257 Thibault, Samid, Tompkins, Figg, Cooper, Hohl, Trepel, Liang, Patronas, Venzon, Reed, Myers (bib27) 1996; 2 West, Fernandez (bib28) 2004; 22 (bib14) 2002; 360 Downs, Clearfield, Weis, Whitney, Shapiro, Beere, Langendorfer, Stein, Kruyer, Gotto (bib8) 1998; 279 Fernandez (bib9) 2001; 131 Grieveson, Ono, Sakakibara, Derrick, Dickinson, McMahon, Higson (bib13) 1997; 252 Nissen, Tuzcu, Schoenhagen, Brown, Ganz, Vogel, Crowe, Howard, Cooper, Brodie, Grines, DeMaria (bib20) 2004; 291 Cannon (10.1016/j.taap.2007.05.005_bib7) 2004; 350 Gordon (10.1016/j.taap.2007.05.005_bib12) 1981; 141 Stein (10.1016/j.taap.2007.05.005_bib26) 1999; 83 (10.1016/j.taap.2007.05.005_bib25) 1994; 344 Sacks (10.1016/j.taap.2007.05.005_bib24) 1996; 335 Flint (10.1016/j.taap.2007.05.005_bib11) 1997; 145 Downs (10.1016/j.taap.2007.05.005_bib8) 1998; 279 Plosker (10.1016/j.taap.2007.05.005_bib23) 2000; 60 Illingworth (10.1016/j.taap.2007.05.005_bib15) 2001; 17 Nishimoto (10.1016/j.taap.2007.05.005_bib18) 2003; 66 Nishimoto (10.1016/j.taap.2007.05.005_bib19) 2003; 13 West (10.1016/j.taap.2007.05.005_bib28) 2004; 22 Grieveson (10.1016/j.taap.2007.05.005_bib13) 1997; 252 Backman (10.1016/j.taap.2007.05.005_bib3) 2002; 72 Matzno (10.1016/j.taap.2007.05.005_bib17) 1997; 38 Thibault (10.1016/j.taap.2007.05.005_bib27) 1996; 2 Fernandez (10.1016/j.taap.2007.05.005_bib9) 2001; 131 Anderson (10.1016/j.taap.2007.05.005_bib2) 1987; 257 Baker (10.1016/j.taap.2007.05.005_bib4) 2005; 31 Johnson (10.1016/j.taap.2007.05.005_bib16) 2004; 200 Nissen (10.1016/j.taap.2007.05.005_bib20) 2004; 291 Amano (10.1016/j.taap.2007.05.005_bib1) 2003; 466 Piper (10.1016/j.taap.2007.05.005_bib22) 2006; 114 Bliznakov (10.1016/j.taap.2007.05.005_bib5) 2002; 56 Brewer (10.1016/j.taap.2007.05.005_bib6) 2003; 92 (10.1016/j.taap.2007.05.005_bib14) 2002; 360 Perez (10.1016/j.taap.2007.05.005_bib21) 2006; 114 Flint (10.1016/j.taap.2007.05.005_bib10) 1997; 145 |
References_xml | – volume: 145 start-page: 91 year: 1997 end-page: 98 ident: bib10 article-title: Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro publication-title: Toxicol. Appl. Pharmacol. contributor: fullname: Durham – volume: 335 start-page: 1001 year: 1996 end-page: 1009 ident: bib24 article-title: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels publication-title: N. Eng. J. Med. contributor: fullname: Braunwald – volume: 344 start-page: 1383 year: 1994 end-page: 1389 ident: bib25 article-title: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) publication-title: Lancet – volume: 145 start-page: 99 year: 1997 end-page: 110 ident: bib11 article-title: HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight protein in neonatal rat muscle cell culture publication-title: Toxicol. Appl. Pharmacol. contributor: fullname: Durham – volume: 60 start-page: 1179 year: 2000 end-page: 1206 ident: bib23 article-title: Cerivastatin publication-title: Drugs contributor: fullname: Figgitt – volume: 141 start-page: 1128 year: 1981 end-page: 1131 ident: bib12 article-title: Lipoproteins, cardiovascular disease, and death: the Framingham Study publication-title: Arch. Intern. Med. contributor: fullname: Dawber – volume: 66 start-page: 2133 year: 2003 end-page: 2139 ident: bib18 article-title: Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A publication-title: Biochem. Pharmacol. contributor: fullname: Sugiyama – volume: 131 start-page: 10 year: 2001 end-page: 20 ident: bib9 article-title: Guinea pigs as models for cholesterol and lipoprotein metabolism publication-title: J. Nutr. contributor: fullname: Fernandez – volume: 2 start-page: 483 year: 1996 end-page: 491 ident: bib27 article-title: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer publication-title: Clin. Cancer Res. contributor: fullname: Myers – volume: 291 start-page: 1071 year: 2004 end-page: 1080 ident: bib20 article-title: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial publication-title: JAMA contributor: fullname: DeMaria – volume: 38 start-page: 1639 year: 1997 end-page: 1648 ident: bib17 article-title: Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts publication-title: J. Lipid. Res. contributor: fullname: Nakamura – volume: 13 start-page: 911 year: 2003 end-page: 918 ident: bib19 article-title: Lipid-lowering property of TAK-475, a squalene synthase inhibitor, in vivo and in vitro publication-title: Br. J. Pharmacol. contributor: fullname: Sugiyama – volume: 360 start-page: 7 year: 2002 end-page: 22 ident: bib14 article-title: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial publication-title: Lancet – volume: 17 start-page: 43 year: 2001 end-page: 50 ident: bib15 article-title: A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial publication-title: Curr. Med. Res. Opin. contributor: fullname: Mitchel – volume: 114 start-page: II-288 year: 2006 ident: bib22 article-title: TAK-475, a squalene synthase inhibitor, improves lipid profile in hyperlipidemic subjects publication-title: Circulation contributor: fullname: Chen – volume: 22 start-page: 55 year: 2004 end-page: 70 ident: bib28 article-title: Guinea pigs as models to study the hypocholesterolemic effects of drugs publication-title: Cardiovascul. Drug Rev. contributor: fullname: Fernandez – volume: 257 start-page: 2176 year: 1987 end-page: 2180 ident: bib2 article-title: Cholesterol and mortality. 30 years of follow-up from the Framingham Study publication-title: J. Am. Med. Assoc. contributor: fullname: Levy – volume: 31 start-page: 572 year: 2005 end-page: 580 ident: bib4 article-title: Molecular clues into the pathogenesis of statin-mediated muscle toxicity publication-title: Muscle Nerve contributor: fullname: Baker – volume: 56 start-page: 56 year: 2002 end-page: 59 ident: bib5 article-title: Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case—a modern Pandora's box publication-title: Biomed. Pharmacother. contributor: fullname: Bliznakov – volume: 114 start-page: II-113 year: 2006 ident: bib21 article-title: Addition of TAK-475 to atorvastatin provides incremental lipid benefits publication-title: Circulation contributor: fullname: Law – volume: 200 start-page: 237 year: 2004 end-page: 250 ident: bib16 article-title: Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone publication-title: Toxicol. Appl. Pharmacol. contributor: fullname: Umbenhauer – volume: 466 start-page: 155 year: 2003 end-page: 161 ident: bib1 article-title: Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia publication-title: Eur. J. Pharmacol. contributor: fullname: Sugiyama – volume: 92 start-page: 23K year: 2003 end-page: 29K ident: bib6 article-title: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams publication-title: Am. J. Cardiol. contributor: fullname: Brewer – volume: 350 start-page: 1495 year: 2004 end-page: 1504 ident: bib7 article-title: Intensive versus moderate lipid lowering with statins after acute coronary syndromes publication-title: N. Engl. J. Med. contributor: fullname: Skene – volume: 83 start-page: 1433 year: 1999 end-page: 1436 ident: bib26 article-title: Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia publication-title: Am. J. Cardiol. contributor: fullname: Heller – volume: 252 start-page: 19 year: 1997 end-page: 23 ident: bib13 article-title: A simplified squalene epoxidase assay based on an HPLC separation and time-dependent UV/visible determination of squalene publication-title: Anal. Biochem. contributor: fullname: Higson – volume: 72 start-page: 685 year: 2002 end-page: 691 ident: bib3 article-title: Gemfibrozil greatly increases plasma concentration of cerivastatin publication-title: Clin. Pharmacol. Ther. contributor: fullname: Neuvonen – volume: 279 start-page: 1615 year: 1998 end-page: 1622 ident: bib8 article-title: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study publication-title: J. Am. Med. Assoc. contributor: fullname: Gotto – volume: 56 start-page: 56 year: 2002 ident: 10.1016/j.taap.2007.05.005_bib5 article-title: Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case—a modern Pandora's box publication-title: Biomed. Pharmacother. doi: 10.1016/S0753-3322(01)00150-0 contributor: fullname: Bliznakov – volume: 344 start-page: 1383 year: 1994 ident: 10.1016/j.taap.2007.05.005_bib25 article-title: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) publication-title: Lancet – volume: 66 start-page: 2133 year: 2003 ident: 10.1016/j.taap.2007.05.005_bib18 article-title: Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2003.08.011 contributor: fullname: Nishimoto – volume: 60 start-page: 1179 year: 2000 ident: 10.1016/j.taap.2007.05.005_bib23 article-title: Cerivastatin publication-title: Drugs doi: 10.2165/00003495-200060050-00011 contributor: fullname: Plosker – volume: 92 start-page: 23K year: 2003 ident: 10.1016/j.taap.2007.05.005_bib6 article-title: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams publication-title: Am. J. Cardiol. doi: 10.1016/S0002-9149(03)00779-3 contributor: fullname: Brewer – volume: 360 start-page: 7 year: 2002 ident: 10.1016/j.taap.2007.05.005_bib14 article-title: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(02)09327-3 – volume: 114 start-page: II-288 issue: Suppl. II year: 2006 ident: 10.1016/j.taap.2007.05.005_bib22 article-title: TAK-475, a squalene synthase inhibitor, improves lipid profile in hyperlipidemic subjects publication-title: Circulation contributor: fullname: Piper – volume: 114 start-page: II-113 issue: Suppl. II year: 2006 ident: 10.1016/j.taap.2007.05.005_bib21 article-title: Addition of TAK-475 to atorvastatin provides incremental lipid benefits publication-title: Circulation contributor: fullname: Perez – volume: 145 start-page: 99 year: 1997 ident: 10.1016/j.taap.2007.05.005_bib11 article-title: HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight protein in neonatal rat muscle cell culture publication-title: Toxicol. Appl. Pharmacol. doi: 10.1006/taap.1997.8174 contributor: fullname: Flint – volume: 252 start-page: 19 year: 1997 ident: 10.1016/j.taap.2007.05.005_bib13 article-title: A simplified squalene epoxidase assay based on an HPLC separation and time-dependent UV/visible determination of squalene publication-title: Anal. Biochem. doi: 10.1006/abio.1997.2309 contributor: fullname: Grieveson – volume: 22 start-page: 55 year: 2004 ident: 10.1016/j.taap.2007.05.005_bib28 article-title: Guinea pigs as models to study the hypocholesterolemic effects of drugs publication-title: Cardiovascul. Drug Rev. doi: 10.1111/j.1527-3466.2004.tb00131.x contributor: fullname: West – volume: 257 start-page: 2176 year: 1987 ident: 10.1016/j.taap.2007.05.005_bib2 article-title: Cholesterol and mortality. 30 years of follow-up from the Framingham Study publication-title: J. Am. Med. Assoc. doi: 10.1001/jama.257.16.2176 contributor: fullname: Anderson – volume: 145 start-page: 91 year: 1997 ident: 10.1016/j.taap.2007.05.005_bib10 article-title: Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro publication-title: Toxicol. Appl. Pharmacol. doi: 10.1006/taap.1997.8131 contributor: fullname: Flint – volume: 83 start-page: 1433 year: 1999 ident: 10.1016/j.taap.2007.05.005_bib26 article-title: Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia publication-title: Am. J. Cardiol. doi: 10.1016/S0002-9149(99)00120-4 contributor: fullname: Stein – volume: 131 start-page: 10 year: 2001 ident: 10.1016/j.taap.2007.05.005_bib9 article-title: Guinea pigs as models for cholesterol and lipoprotein metabolism publication-title: J. Nutr. doi: 10.1093/jn/131.1.10 contributor: fullname: Fernandez – volume: 141 start-page: 1128 year: 1981 ident: 10.1016/j.taap.2007.05.005_bib12 article-title: Lipoproteins, cardiovascular disease, and death: the Framingham Study publication-title: Arch. Intern. Med. doi: 10.1001/archinte.141.9.1128 contributor: fullname: Gordon – volume: 17 start-page: 43 year: 2001 ident: 10.1016/j.taap.2007.05.005_bib15 article-title: A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial publication-title: Curr. Med. Res. Opin. doi: 10.1185/03007990152005351 contributor: fullname: Illingworth – volume: 13 start-page: 911 year: 2003 ident: 10.1016/j.taap.2007.05.005_bib19 article-title: Lipid-lowering property of TAK-475, a squalene synthase inhibitor, in vivo and in vitro publication-title: Br. J. Pharmacol. doi: 10.1038/sj.bjp.0705332 contributor: fullname: Nishimoto – volume: 72 start-page: 685 year: 2002 ident: 10.1016/j.taap.2007.05.005_bib3 article-title: Gemfibrozil greatly increases plasma concentration of cerivastatin publication-title: Clin. Pharmacol. Ther. doi: 10.1067/mcp.2002.128469 contributor: fullname: Backman – volume: 31 start-page: 572 year: 2005 ident: 10.1016/j.taap.2007.05.005_bib4 article-title: Molecular clues into the pathogenesis of statin-mediated muscle toxicity publication-title: Muscle Nerve doi: 10.1002/mus.20291 contributor: fullname: Baker – volume: 2 start-page: 483 year: 1996 ident: 10.1016/j.taap.2007.05.005_bib27 article-title: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer publication-title: Clin. Cancer Res. contributor: fullname: Thibault – volume: 279 start-page: 1615 year: 1998 ident: 10.1016/j.taap.2007.05.005_bib8 article-title: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study publication-title: J. Am. Med. Assoc. doi: 10.1001/jama.279.20.1615 contributor: fullname: Downs – volume: 350 start-page: 1495 year: 2004 ident: 10.1016/j.taap.2007.05.005_bib7 article-title: Intensive versus moderate lipid lowering with statins after acute coronary syndromes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa040583 contributor: fullname: Cannon – volume: 335 start-page: 1001 year: 1996 ident: 10.1016/j.taap.2007.05.005_bib24 article-title: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels publication-title: N. Eng. J. Med. doi: 10.1056/NEJM199610033351401 contributor: fullname: Sacks – volume: 466 start-page: 155 year: 2003 ident: 10.1016/j.taap.2007.05.005_bib1 article-title: Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia publication-title: Eur. J. Pharmacol. doi: 10.1016/S0014-2999(03)01549-8 contributor: fullname: Amano – volume: 200 start-page: 237 year: 2004 ident: 10.1016/j.taap.2007.05.005_bib16 article-title: Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone publication-title: Toxicol. Appl. Pharmacol. doi: 10.1016/j.taap.2004.04.010 contributor: fullname: Johnson – volume: 291 start-page: 1071 year: 2004 ident: 10.1016/j.taap.2007.05.005_bib20 article-title: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.291.9.1071 contributor: fullname: Nissen – volume: 38 start-page: 1639 year: 1997 ident: 10.1016/j.taap.2007.05.005_bib17 article-title: Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts publication-title: J. Lipid. Res. doi: 10.1016/S0022-2275(20)37182-0 contributor: fullname: Matzno |
SSID | ssj0009441 |
Score | 2.0786996 |
Snippet | High-dose statin treatment has been recommended as a primary strategy for aggressive reduction of LDL cholesterol levels and protection against coronary artery... |
SourceID | osti proquest crossref pubmed pascalfrancis elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 39 |
SubjectTerms | 60 APPLIED LIFE SCIENCES ACETATES Animals Biological and medical sciences Biomarkers - metabolism CHOLESTEROL Cholesterol - blood COENZYMES CORONARIES CREATINE Creatine Kinase - metabolism Drug Antagonism Drug Therapy, Combination Enzyme Inhibitors - pharmacology Farnesyl-Diphosphate Farnesyltransferase - antagonists & inhibitors GUINEA PIGS Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects IN VIVO INHIBITION Lapaquistat acetate Male Medical sciences Mevalonic Acid - analogs & derivatives Mevalonic Acid - pharmacology Muscle, Skeletal - drug effects Muscle, Skeletal - enzymology Muscle, Skeletal - pathology Muscular Diseases - chemically induced Muscular Diseases - pathology Muscular Diseases - prevention & control Myotoxicity Oxazepines - pharmacology Piperidines - pharmacology Pyridines - adverse effects SIDE EFFECTS SQUALENE Squalene synthase inhibitor Statin TAK-475 TOXICITY Toxicology |
Title | Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs |
URI | https://dx.doi.org/10.1016/j.taap.2007.05.005 https://www.ncbi.nlm.nih.gov/pubmed/17599378 https://search.proquest.com/docview/19739541 https://www.osti.gov/biblio/21077778 |
Volume | 223 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB612wsSQlBeKWXxAVUgNjQPe50cVxXVQqVqD1tpb5Gd2G0QJNsmK7EXxE9nZp0o6qEcuNqeyPGMZ8b2zDcA7w1hFUaB9vNQWjygTK2fppr7xgoZkAiFZhdtcTmdX_FvK7Hag7M-F4bCKjvd73T6Tlt3Lafdap6uy5JyfDkh06xQaAkHb7UPB2iOOB_BwezrxfxywN7l3BXO43hyRoIud8aFebVKrTskQ7pdEQ_Zp1GNW44iJ1WDi2dd1YuH3dKdeTp_Ck86v5LN3NSfwZ6pDuFk4YCptxO2HPKsmgk7YYsBsnp7CI_d7R1zSUnP4c_CwTegKmRdxAerLVOsoSRMVI-s2VbtDVpAVlY3pUa1cDdhP9Dw3m7IIW2ZyimO0bAPy9mFz6X4OGF1xairrPyyKlCiCvZzW7f1rzLHkwB-h11v0OVVbF1eNy_g6vzL8mzud7Ua_JzzuPUTLgITcV1wHSuba2XiJCpEagIjCMCiMElspZQ6wHHaYpvUMtVoQ3kaWJXEL2FU1ZV5DSxXVDVU5nZKRccldoaqiLTIlc6tjqwHn3oOZWsHyZH1sWrfM-In1daUWSAy5KcHomdidk-wMrQZ_6Q7Jo4TDaHp5hR2hER4Qsa_kIkH43uSMMwkpTKH08CDd71oZLhj6RlGVabeNDiCHkd56MErJzEDrRTkLiZH_znnN_DIXT0nfiiOYdTebcxb9JlaPYb9z7_Dcbcz_gJeaxYW |
link.rule.ids | 230,315,786,790,891,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6V5QBShaC8AqX1AVUgNm0e9jo5VhXVQku1h620t8hO7DaIJkuTldgL4qczs04U9VAOXP2InMx4Zux88w3Ae0NchVGg_TyUFg8oE-unqea-sUIGpEKh2aAtLibTS_51IRZbcNLnwhCssrP9zqZvrHXXctR9zaNlWVKOLydmmgUqLfHgLR7AQ4oGCNd1-HvAeaScu7J5HM_NOLzLnHEgr1apZcdjSHcr4j7vNKpxwxFuUjX46ayreXF_ULpxTqdP4UkXVbJjt_BnsGWqHTiYOVrq9ZjNhyyrZswO2GwgrF7vwLa7u2MuJek5_Jk58gY0hKzDe7DaMsUaSsFE48iaddVeo_9jZXVdajQKt2P2A93uzxWFoy1TOaEYDfswPz7zuRQfx6yuGHWVlV9WBepTwW7WdVv_KnM8B-Bz2NUKA17FluVV8wIuTz_PT6Z-V6nBzzmPWz_hIjAR1wXXsbK5ViZOokKkJjCC6CsKk8RWSqkDHKcttkktU40elKeBVUn8EkZVXZnXwHJFNUNlbidUclxiZ6iKSItc6dzqyHrwqZdQtnSEHFmPVPuekTypsqbMApGhPD0QvRCzO2qVocf457xdkjjNIS7dnEBHOAnPx_gWMvFg744mDCtJqcjhJPBgv1eNDPcr_YRRlalXDY6gX6M89OCV05hhrhQULCZv_nPN-_BoOv92np1_uTh7C4_dJXTih2IXRu3tyrzD6KnVe5vd8RfdBRbr |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protective+effects+of+a+squalene+synthase+inhibitor%2C+lapaquistat+acetate+%28TAK-475%29%2C+on+statin-induced+myotoxicity+in+guinea+pigs&rft.jtitle=Toxicology+and+applied+pharmacology&rft.au=NISHIMOTO%2C+Tomoyuki&rft.au=ISHIKAWA%2C+Eiichiro&rft.au=ANAYAMA%2C+Hisashi&rft.au=HAMAJYO%2C+Hitomi&rft.date=2007-08-15&rft.pub=Elsevier&rft.issn=0041-008X&rft.eissn=1096-0333&rft.volume=223&rft.issue=1&rft.spage=39&rft.epage=45&rft_id=info:doi/10.1016%2Fj.taap.2007.05.005&rft.externalDBID=n%2Fa&rft.externalDocID=19018760 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-008X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-008X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-008X&client=summon |